Since mammalian atria were recently found to contain vasoactive and natriuretic peptides, we investigated the following in normal humans: plasma human atrial natriuretic peptide concentrations, effective renal plasma flow (ERPF), glomerular filtration rate (GFR), urinary water and electrolyte excretion, blood pressure (BP), and catecholamine, antidiuretic hormone (ADH), angiotensin II, and aldosterone levels before, during, and after intravenous administration of the newly synthetized alpha-human atrial natriuretic peptide (ahANP).
Introduction
Cardiac atria of several species, including man, contain a group of peptides with vasorelaxant, blood pressure (BP)'-lowering, 1 . Abbreviations used in this paper: ADH, antidiuretic hormone; ANP, atrial natriuretic peptide(s); BP, blood pressure; ERFP, effective renal plasma flow; FF, filtration fraction; GFR, glomerular filtration rate; ahANP, alpha-human atrial natriuretic peptide; PAH, paraamino hippuric acid. and natriuretic properties (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . The possibility of a physiological role ofatrial natriuretic peptide(s) (ANP) in the regulation of sodium fluid volume homeostasis is supported by altered granularity of cardiocytes ( 11) and atrial contents of natriuretic factor (12) in response to variations in hydration, and by the presence of measurable ANP levels, which are increased by acute saline loading, in the circulation of the rat (13) . Effects of ANP on kidney function have been evaluated in experimental. animals.
Micropuncture studies were interpreted as evidence for a renal tubular action of atrial extracts, with inhibition of sodium reabsorption along the medullary collecting ducts in the presence of an unchanged glomerular filtration rate (GFR) (14, 15) . However, while GFR was apparently unaltered in the unsteady state after single-dose injection (1, (15) (16) (17) (18) , distinct increases in GFR and, thus, filtered loads ofsodium, were noted during a constant infusion of rat atrial extract or synthetic ANP in the isolated kidney (19, 20) and in some (21) (22) (23) , but not all (24) , studies in the intact rat or dog. On the other hand, total renal blood flow was variably reported as increased (20, 25, 26) , unchanged (16, (22) (23) (24) , or after an initial rise, even decreased (21) . An intrarenal shift ofblood flow from the outer to the inner cortex and medulla was also described (12, 25) and considered to contribute to ANPinduced sodium diuresis via washout of urea in the papilla.
Whether ANPs are released into the human circulation and whether they may modify renal function in man has been unknown. Therefore, we investigated plasma ANP concentrations, effective renal plasma flow (ERPF), GFR, urinary excretion of water and various electrolytes, blood levels of renin, angiotensin II, aldosterone, antidiuretic hormone, catecholamines, and BP before, during, and after a constant infusion ofthe alpha-human atrial natriuretic peptide (ahANP) in normal man. The newly synthetized ahANP (Bissendorf Peptide GmbH, Wedemark, Federal Republic of Germany) is the synthetic replicate of the 28-residue active peptide (3,082.6 mol wt) at the COOH-terminal end of yhANP (13,000 mol wt).
Methods
Study A. 10 normal subjects (five women, five men) aged 23-29 yr (mean±SD, 26±1.9 yr) were studied. They were healthy volunteers with a BP consistently <140/90 mmHg and no evidence ofany disease. None ofthe subjects were taking any drugs. Nicotine and alcohol abusers were excluded. After having given their written informed consent to the study, they were instructed to eat a normal diet, avoiding very low or high salt intakes (27) for at least 5 d before the study.
The following procedure was then performed: a 24-h urine was collected for determinations ofsodium, chloride, potassium, calcium, magnesium, phosphate, uric acid, urea and creatinine excretion rates, and osmolality. At the completion ofthe urine collection, renal function and a varietyofadditional factors were evaluated under steady state conditions were inserted on each arm into an antecubital vein. GFR and ERPF were determined by constant infusion clearance technique, using 5"Cr-EDTA and paraamino hippuric acid (PAH), respectively (28). At 8 a.m.
an intravenous priming dose of 25 uCi 5"Cr-EDTA and 0.6 g PAH in 50 ml NaCl (0.9%) was administered, followed by a maintenance infusion of a solution containing 7.5 MCi 5"Cr-EDTA and 0.4 g PAH/100 ml NaCl by a calibrated pump (infusion type 5094, Steril Catgut Gesellschaft, Neuhausen, Switzerland) at a rate of 3 ml/min. For blood sampling, the venous access on the contralateral arm was used and blood was allowed to drip freely whenever possible. Urine sampling was obtained by catheter and rinsing with air as well as distilled water, 20 ml twice per urine collection. Urine produced during an initial 45-min equilibration period was discarded. Starting at 8:45 a.m., two urine collection periods served as control phase. During the 45 min of clearance periods 3-5, ahANP was infused intravenously (ahANP infusion phase). A bolus injection of 50 Mg ahANP in I ml 0.9% NaCl was followed by a maintenance infusion at a rate of 6.25 Mg/min (on average 0. M jg/min per kilogram body weight, which in the subjects ranged from 50 to 80 kg); the infusion solution (300 Mg ahANP in 45 ml 0.9% and 3 ml 20% human serum albumin) was delivered by a calibrated pump (Perfusor V; B. Braun Apparatebau, Melsungen, Federal Republic of Germany). No ahANP was infused during clearance periods 6-8 (recovery phase). 17 ml of 20% human serum albumin were infused slowly during periods 6 and 7 to limit the tendency for hypovolemia due to blood sampling (270 ml up to period 7, 330 ml up to period 8).
Body weight was recorded before and at completion of the test. BP and heart rate were obtained at 1-3-min intervals during clearance periods 3, 4, and 6, and at 2-5-min intervals during periods 1, 2, 5, 7, and 8.
Hematocrit, plasma protein, urine volume and pH, and plasma and urinary sodium, chloride, potassium, calcium, magnesium, phosphate, osmolality, uric acid, urea, creatinine, 5"Cr-EDTA, and PAH values were measured in each clearance period. Plasma renin activity, angiotensin II, aldosterone, norepinephrine, epinephrine, dopamine, and antidiuretic hormone (ADH) levels were determined in clearance periods 2 (control value), 5 (end of ahANP infusion), and 8 (end of recovery phase); while plasma ahANP concentrations were measured in clearance periods 2 and 5-8.
Study B. Three normal men aged 30 yr were studied. Criteria for inclusion and exclusion were similar to those used in Study A. The study protocol was also identical, except that a double dose of ahANP was administered, specifically, an intravenous bolus of 100 jtg at the beginning of clearance period 3, followed by a maintenance dose of 12.5 Mg/min until the end ofclearance period 5. Body weight in these subjects ranged from 65 to 80 kg.
Analytical methods. BP was determined with standard cuff and the semiautomatic recorder Sphygmo-Digital (Asulab, Neuchitel, Switzerland); the mean reading over 7.5-min intervals (half a clearance period) was used for analyses. Hematocrit was measured by the microcrit method, plasma and urinary 5"Cr activity in a -y-counter (Tri-Crab-Scintillation spectrometer, Packard Instrument Co., Downers Grove, IL), PAH by standard photometric method, sodium and potassium by flame photometer, and chloride, calcium, magnesium, phosphate, uric acid, urea, and creatinine by autoanalyzer (Greiner Societ6 Anonyme, Langenthal, Switzerland). Osmolality was measured by freezing point depression using a cryoscope with Peltier's element, plasma protein by the biuret method, and plasma renin activity, angiotensin II, and aldosterone levels by radioimmunoassay (29) (30) (31) , as reported previously from our laboratory (27, 32) . Plasma and urinary norepinephrine, epinephrine, and dopamine were determined with high performance liquid chromatography and electrochemical detection using a modified method ofSmedes et al. (33) . Plasma ADH levels were measured by radioimmunoassay (34) . Plasma ANP concentrations were determined by a high performance liquid chromatography-radioimmunoassay. Plasma was extracted by passing through ODS-silica cartridges according to the procedure recently described for rat plasma (13) . The 10 normal subjects averaged 58±12 pg/ml under control conditions, was increased to 625±87 pg/ml during ahANP infusion at a rate of 6.25 ,g/min (P < 0.01), and rapidly fell thereafter, almost reaching control values at 37.5 min of the recovery phase (Table I , Fig. 1 ).
Clinical, some biochemical, and endocrine parameters.
Compared with control values, systolic BP was decreased slightly during ahANP infusion (on average -7% at the end of the infusion, P < 0.001) and remained at the latter level (around -7%, P < 0.001) during the recovery phase (Table I, Fig. 2 ). Diastolic BP was lowered distinctly during ahANP infusion (-12% at the end of the infusion, P < 0.001) and returned partly towards control values during the recovery phase. Heart rate was increased by 10-16% throughout the ahANP infusion and recovery phase (P < 0.001).
Hematocrit and serum protein concentrations rose acutely by an average of 5% between 0-and 1 5-min ahANP infusion and by 7% between 15 and 45 min of infusion; both parameters were restored towards control values at the end of the recovery period (Table I) . Based on the changes in hematocrit and plasma protein, the calculated plasma volume (4.5% of body weight = 2.79 liter) fell within 15 min of ahANP infusion by 140 ml and within 30 min by 195 ml (removal of whole blood for analytical procedures not considered), while a balanced intra-and extravascular depletion of calculated functional extracellular fluid volume (21% body weight = 13 liter) would have decreased the latter by 910 ml. However, urinary output exceeded intravenous input of normal saline by only 12 ml between 0 and 15 min of ahANP infusion, by 76 ml between 15 and 30 min, and by 57 ml between 30 Figure 2 . Effect of ahANP, a 50 ,g bolus followed by maintenance infusion of 6.25 Mg/min, on BP and heart rate in 10 normal subjects (mean±SEM). The mean of the two control values is taken as 100%.
Plasma renin activity, angiotensin II, aldosterone, ADH, epinephrine, and dopamine levels were not significantly modified during the procedure (Table I) . Plasma norepinephrine levels were elevated (P < 0.001) during ahANP infusion and restored to control values thereafter.
Renal function and plasma and urinary electrolytes. Compared with the mean value of the two control clearance periods, ERPF was not significantly changed during ahANP infusion and decreased (P < 0.05) during the first 30 min ofthe recovery phase (Table II, Fig. 3 ). In contrast, GFR was modestly increased (+ 15% on average, P < 0.05) and FF was markedly increased (+37%, P < 0.001) during ahANP infusion. GFR returned completely to control levels and FF almost to control levels during the recovery phase.
Urine flow and sodium, chloride, magnesium, calcium, phosphate, and osmolal excretion rates were increased significantly (P < 0.01 to <0.001) during ahANP infusion (Table II, Figs. 4 and 5). Maximal percentage increases of absolute excretion rates were +495% on average for urine flow, +317% for chloride, +224% for sodium, + 158% for calcium, +110% for magnesium, and +88% for phosphate. Maximal percentage increases of fractional excretion rates were +261% for chloride, + 179% for sodium, + 114% for calcium, +75% for magnesium, and +75% for phosphate. Urinary potassium excretion was increased only slightly (P < 0.01, +53%) during the first 30 min and was already restored to control levels between 30 and 45 min of ahANP infusion (Fig. 4) .
During the two clearance periods between 15 and 45 min of ahANP infusion, the mean increases in urine flow rate (+6.6 and 5.8 ml/min, respectively) corresponded to 33 and 32% of the increase in GFR (+20 and +18 ml/min per 1.73 m2). The increases in sodium excretion rate (+415 and +395 ,mol/min) corresponded to 14.4 and 15.2% of the increases in filtered load of sodium (+2880 and +2590 Mmol/min); thus, absolute sodium reabsorption increased by +2465 and +2195 ,umol/min, re- Compared with control conditions, urinary osmolality was decreased by 48% during ahANP infusion (P < 0.01), while free water clearance was increased (P < 0.001) ( 6) were also twice those induced by the lower ahANP infusion rate (Fig. 2) ; heart rate was no longer increased at the time of the greatest fall in BP, despite a preceeding transient increase. He during the ahANP infusion and by 25±3% at the end of the recovery phase.
During double-dose ahANP infusion, maximal percentage changes in absolute excretion rates of volume (on average +333±140%), sodium (+273±51%; Fig. 7 ), chloride (+326±57%), potassium (+90±9%), magnesium (+89±28%), calcium (+ 129±41%), and phosphate (+42±8%) did not exceed those produced by the lower ahANP infusion rate; moreover, maximal urinary excretion rates during double-dose infusion were limited to the first 30 min and subsequently fell back to control values during the last 15 min ofinfusion (Fig. 7) . Changes in urinary osmolality were quite similar to those obtained with the lower ahANP infusion rate, while free water clearance again tended to be increased (Fig. 7) .
Side effects. Nausea accompanying marked decreases in BP with unchanged or even slowed heart rate occurred during the last 15 min of ahANP infusion or early in the recovery phase in three subjects in study A and in one subject in study B. Transient facial flushing developed in one subject after the initial bolus injection in study B. Peptides of human atrial origin have been isolated, characterized, and synthetized (7) . The short half-life of plasma ahANP, as evidenced by the rapid fall of plasma concentrations after discontinuation of ahANP, suggests that the endogenous blood levels in normal man can be maintained only by a similar efficient rate of secretion or production. The role of the heart as an endocrine gland which provides the human circulation with ANP is supported by the recent demonstration of an identical ANP released from heart tissue and present in the plasma of rats ( 13) or coronary venous effluent of rabbit or rat heart (35) (36) (37) . The possibility of a production in extracardiac tissue such as brain (37, 38) must also be considered. Nevertheless, isolation from plasma and sequencing of the peptide will be required for a definite clarification of the structure of circulating hANP.
The acute fall (10% or more) in diastolic BP within the first minutes of single bolus injection (9, 10) and constant infusion of ahANP in initially well-hydrated normotensive subjects points to a potent cardiovascular action of ahANP in normal man. A similar rapidity of the BP-lowering effect of ANP in experimental animals, its persistence in the anephric state (12) , and an acute decrease in total peripheral vascular resistance (25, 39) also indicated that overall body sodium fluid volume depletion is not required as a mechanism. The smooth muscle cells of rat and rabbit aorta contain specific receptors for ANP (40, 41) , and the latter activates particulate guanylate cyclase which, in turn, elevates cyclic guanosine monophosphate in vascular smooth muscle (42). In aortic or renal artery preparations of rat, rabbit, or dog, atrial extracts or peptides were reported to antagonize the vasoconstrictor effect ofboth norepinephrine and angiotensin 11 (5, 6, 19, 20, 43, 44) . Tn normal man, however, ahANP acutely counteracted the pressor action of norepinephrine more than that of angiotensin II (9) . This suggests that ahANP may, at least in humans, interact preferentially with noradrenergic cardiovascular control.
Intravascular volume contraction is probably a complementary factor in the BP-lowering mechanism of ahANP. However, although ahANP infusion at a rate of 6.25 ug/min (study A) was associated with a net negative body fluid balance of 235 ml, the initial decrease in BP occurred before a relevant extracellular fluid depletion (-20 ml whole blood and 12 ml excess urine output during the first 15 min), and fluid balance during the entire test was even slightly positive (+70 ml). Moreover, during the procedure with double-dose ahANP infusion (study B), BP tended to fall even more markedly despite no negative overall fluid balance (+0.20 liter). Considering the corresponding fluid input and output rates, the 6% or greater rises in hematocrit and plasma protein concentration during ahANP infusion indicate a greater degree of intravascular than overall extracellular fluid volume contraction. The rapid restoration of hematocrit and plasma protein towards control values during the recovery phase also supports the occurrence ofa readily reversible extravascular shift of fluid accompanying the ahANP infusion. Such transfer could be due to an increase in capillary permeability and/or filtration pressure.
Whether and to what extent ANP may modify the activity of the sympathetic nervous system has been largely unknown. Plasma norepinephrine levels and heart rate were increased significantly (P < 0.001) during ahANP infusion in our normal subjects. Urinary norepinephrine excretion rate also tended to rise, while plasma and urinary epinephrine and dopamine levels were rather stable. This constellation probably reflects baroreflex activation of the efferent sympathetic nerves secondary to the decreases in BP. Thus, regulatory relationships in the normal human may again differ from certain animal experiments in which heart rate in the presence of an acutely lowered BP was unchanged or even decreased (39, 45) by atrial extracts or ANP. Nevertheless, four of our normal subjects developed nausea and signs of a vagal reaction towards or shortly after the end of the ahANP infusion, as evidenced by a stable or slowing heart rate despite a marked fall in BP. The latter constellation was particularly evident during the last 15 min of high dose ahANP infusion in study B. Therefore, variable net chronotropic influences of ahANP may reflect a predominant sympathetic response during shorter or low dose infusion and an inappropriate rise in efferent vagal tone with increased dose and/or duration of infusion. In the rat, atrial extract seems to promote its BP-lowering and a bradycardic effect via afferent vagal fibres which may be activated via chemosensitive cardiopulmonary receptors (39). A direct action on ANP on cardiac tissue is not excluded.
ERPF tended to decrease progressively during ahANP infusion in our normal subjects. A similar trend has been noted in the anesthetized dog or rabbit (21, 46) , although consistent decreases (22) , unchanged values (16, 18, 23, 24) , or even dosedependent increases (1, 25, 26) in total renal blood flow were noted in other animal experiments, some of which were based on injection ofrather than constant infusion ofANP. Increasing the ahANP infusion rate from 6.25 to 12.5 ,ug/min in the normal subjects was accompanied by a greater fall in ERPF. ANP may modify renal perfusion indirectly through the lowered systemic pressure and hemoconcentration; a vasoconstrictor influence of sympathetic activation could also play a mediating role. Furthermore, ANP may directly promote renal vasoconstriction under basal conditions and vasodilation when renal vessels are preconstricted by norepinephrine or angiotensin 11 (6, 19, 20, 24) . Plasma renin and angiotensin II levels were normal in our untreated healthy subjects and not significantly modified during ahANP infusion. The latter could theoretically limit the value ofthe ERPF estimate by decreasing PAH extraction rate through inhibition of tubular secretion and/or an increase in medullary blood flow (12, 25) . PAH clearance correctly indicated changes in renal blood flow in dogs receiving an ANP infusion (21), but no measurements ofPAH extraction rate were performed in this human study.
The increase in GFR (on average + 15%, P < 0.05) despite decreased BP and ERPF, with the FF rising by an impressive 44% (P < 0.01), represents a unique renal action of ahANP in man. It has also been noted in the anesthetized dog (21, 47) , while an increased GFR without change in total renal blood flow has been observed in the rat (22, 23) . A constriction of the efferent accompanied by a dilatation of the afferent glomerular arterioles, as suspected during ANP infusion in the isolated rat kidney (6, 20) , may elevate the glomerular capillary hydraulic pressure and, thus, increase GFR despite the reduction of renal blood flow (48) . On the other hand, there is evidence against an increase in the glomerular permeability (48, 49) and the reported medullary redistribution of renal blood flow (12, 25) may also fail to explain the ANP-induced rise in GFR (23) .
The marked increases in urine flow (up to fivefold) and excretion rates of chloride (threefold), sodium (twofold), calcium (1.5-fold), magnesium, and phosphate (both approximately doubled) during ahANP infusion at 6.25 ,gg/min in our normal subjects were at least in part due to the distinct rise in the filtered loads of fluid and electrolytes. In fact, only 15% ofthe increment in filtered sodium load were excreted, while 85% were reabsorbed; corresponding values for chloride were 19 and 81%, respectively. The small rise in the fractional excretion rates of sodium and chloride from 1.1 and 1.3%, respectively, during control conditions to about 3.0 and 3.7% during ahANP infusion in normal humans could possibly be an appropriate consequence of the acutely increased GFR, as recently demonstrated in the rat (23) . In the present study, the infusion of 0.9% NaCl as carrier solution for PAH, 5"Cr-EDTA, and ahANP could have favored an exaggeration of the apparent excretory responses to ahANP and a delayed return of excretory parameters to control values during the recovery phase. However, such an influence should have been minimal, since the NaCl infusion at a rate of 3 ml/min, rather than representing a load, served to prevent sodium fluid volume depletion due to the sampling of blood in closely corresponding amounts.
Free water clearance was increased markedly during ahANP infusion in the normal humans. Although such a tendency was also noted after injection ofrat atrial extract into isolated perfused rat kidneys (19) , free water clearance was unchanged or even decreased during ahANP infusion in intact rats, dogs, or monkeys (16, 17, 21, 25, 47) .
How much a given increase in GFR will augment the excretion ofwater and electrolytes is difficult to judge. Nevertheless, some observations obtained with substances that are not known to have transport inhibitory properties are available. In the dog, infusions of glycine or glucagon increased GFR by 17 and 31%, respectively; sodium excretion was augmented by only 68 and 135%, respectively, although both substances also caused a 20-30% rise in renal blood flow (50). In man, it is possible to increase GFR without marked changes in BP by hydralazine or pyrogenic substances. Under such circumstances there is a direct linear correlation between the percentage changes in GFR and the concomitant changes in urine flow rate (hydralazine, n = 48, r = 0.56, P < 0.001, y [flow rate] = 3.48 X -232; pyrogen, n = 21, r = 0.66, P < 0.001, y = 2.58 X -143) or the changes in urinary sodium excretion (pyrogen, n = 21, r = 0.64, P < 0.001, y [sodium excretion] = 2.94 X -176) (Reubi, F. C., unpublished observations). According to the calculated relationships, a 15% increase in GFR, such as observed in the present ahANP experiments of study A, should produce a 54-68% rise in volume and sodium excretion. These values are quite close to those observed during glycine infusion in the dog (50). It appears therefore, that for a given increase in GFR, ahANP may cause an at least twofold greater natriuresis and diuresis than these other vasoactive substances.
The excretory component in ahANP's action that is not explained by increased GFR alone may be mediated by additional renal hemodynamic, humoral, or even direct tubular effects.
An inner cortical and medullary shift of renal plasma flow (12, 25) and a rise in papillary plasma flow (12) were observed after administration of atrial extracts to rats. The resultant washout of urea from the papilla might lead to a disruption of the counter current gradients with reduction of sodium reabsorption in the thick ascending limb of the deep nephrons. The latter sequence ofevents may have modulated sodium excretion in the normal humans while their ERPF was unchanged or only slightly decreased; while a more marked fall in ERPF such as observed during high dose ahANP infusion may well have minimized or even precluded any relevant natriuresis from medullary hyperperfusion by redistribution. The increased tubular flow rate and urea washout could also account for the dissociation between water and sodium excretion. In fact, the increment in free water clearance lagged behind the rise in sodium and chloride excretion, as evidenced by still unchanged free water clearance despite significantly increased natriuresis and chloruresis (P < 0.001) during the initial 15 min of ahANP infusion. Nevertheless, it is difficult to interpret changes in free water clearance in nonwater-loaded subjects.
Considering humoral factors, blood levels of ADH, aldosterone, and dopamine, as well as urinary dopamine excretion rates were unchanged at 37 min of ahANP infusion in the present study. Nevertheless, circulating aldosterone was reduced in anesthetized dogs (21) , and atrial extracts lowered aldosterone production in isolated adrenal cells of rat or other animals (51-52). The noradrenergic activation may in some way contribute, since chemical sympathectomy or a-receptor blockade diminished the diuretic and natriuretic responses to atrial extract in the rat (53) . Moreover, an enhanced production of renal prostaglandin E (54) or kallikrein (55) could play a complementary role and also antagonize the tubular action of ADH.
The present findings do not permit us to delineate or rule out a direct tubular action of ahANP. Micropuncture studies in the rat indicated that sodium reabsorption in accessible segments of superficial nephrons and in Henle's loop is not decreased by atrial extract or ANP (14, 15, 23) . However, a direct inhibitory influence on more distal sodium reabsorption in the rat was postulated (14, 15, 18) . This concept, as well as the theoretical possibilities of altered peritubular Starling forces, an enhanced permeability of collecting ducts with a resultant net transfer of sodium from the interstitium to duct fluid, an interference of ahANP with the tubular action of ADH, or a direct inhibition ofosmotic water flow in the collecting system, remains to be clarified. Whatever the exact interactions, the presence of ANP receptors on cultured tubular cells of the rabbit (41) and an ANP-induced rise in particulate guanylate cyclase and cyclic guanosine monophosphate in rat kidney tissue and in canine glomeruli, collecting duct, and ascending thick Henle's loop (56) are consistent with an influence ofANP on renal tissue at various levels.
